Stenoparib - Allarity Therapeutics
Alternative Names: 2X-121; 2X-121/PARPi; E-7449; MGI 25036Latest Information Update: 12 Jun 2025
At a glance
- Originator Eisai Co Ltd
- Developer Allarity Therapeutics
- Class Antineoplastics; Antivirals; Isoindoles; Pyridazines; Quinazolines; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors; Tankyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Ovarian cancer
- Phase I/II Solid tumours
- No development reported B-cell lymphoma; COVID 2019 infections; Neuroblastoma; Renal cancer; Sarcoma
Most Recent Events
- 04 Jun 2025 Allarity Therapeutics enters into a research agreement with Indiana Biosciences Research Institute for understanding of the dual mechanism of action of Stenoparib
- 09 May 2025 Allarity Therapeutics plans a phase II trial for Small-cell lung cancer (Combination therapy) by the third quarter of 2025
- 17 Mar 2025 Adverse events data from a phase II (PREDICT 2X-121)trial in Ovarian cancer released by Allarity Therapeutics